Clinical Indication

Primary prevention of osteoporotic fragility in menopausal women


Not recommended in NICE TA 160

Date of classification

July 2018

Review date

July 2021


Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.

All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.